PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Hormonal and reproductive

PT-141 (bremelanotide)

Also written as: Bremelanotide, PT-141, PT 141, Vyleesi, BMT

PT-141 is the code name for bremelanotide, a man-made peptide that switches on melanocortin receptors; it is an FDA-approved prescription medicine (Vyleesi) for low sexual desire in premenopausal women, with a modest effect in two large trials, and the "PT-141" sold online is not that approved medicine.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • Bremelanotide is approved in the United States as Vyleesi, only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
  • The label says it is not approved for women after menopause, for men, or to enhance sexual performance.
  • In two 24-week trials of 1,267 women, it raised desire scores and lowered distress scores more than placebo, but the extra gain was small (about a third of a point on a 1.2 to 6 desire scale), and the number of satisfying sexual events did not improve.
  • Nausea affected 40% of women in the trials, against 1% on placebo. It briefly raises blood pressure after each use and can cause dark patches on the skin and gums.
  • In August 2026 the FDA told online sellers that their "PT-141" products were unapproved new drugs, despite "research use only" labels.
  • It is not named on the WADA Prohibited List for 2026 or 2027, and no WADA ruling on it was found.

What it is

PT-141 is the development code for bremelanotide. It is a synthetic peptide, a short chain of amino acids (the building blocks of proteins). It is made of seven amino acids joined into a ring. It activates melanocortin receptors, docking sites on cells that normally respond to hormones such as alpha-melanocyte-stimulating hormone (alpha-MSH). The FDA label calls it a melanocortin receptor agonist. An agonist is a substance that switches a receptor on.

More on what it is and where it came from

In the United States it is a prescription medicine sold as Vyleesi, an injection under the skin. The FDA approved it on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or difficulty in relationships, that began after a time of normal desire, that happens in every situation and with every partner, and that is not caused by another medical or mental health condition, relationship problems, or a medicine or drug. The label states it is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance. As of November 2026 the product is marketed by Cosette Pharmaceuticals.

Products labeled "PT-141" are also sold online as "research use only" powders. In August 2026 the FDA sent warning letters to sellers stating that such products were unapproved new drugs. None of the trials on this page tested those products. Nothing on this page is advice about using any form of bremelanotide.

Bremelanotide was developed by Palatin Technologies, which the phase 3 paper calls the innovator of the drug and which sponsored the main trials. Early papers from Palatin scientists (2003 and 2004) described it as a cyclic peptide related to alpha-MSH and tested a nasal spray in men with erectile dysfunction. An FDA review notes it had a development period of about 20 years, that the erectile dysfunction program in men did not lead to an approved product, and that the nasal-spray program in men was formally withdrawn in 2017. Work in women began under a separate application opened in 2001, first with a nasal spray and later with an injection. Its chemical structure, as recorded on PubChem, is the same as that of melanotan II (an older, unapproved tanning peptide) except at one end of the chain, where bremelanotide has an acid group and melanotan II has an amide group. It is often described as a metabolite (breakdown product) of melanotan II; no primary source confirming that description was found for this page. The FDA application, first held by AMAG Pharmaceuticals at approval in 2019, was transferred to Palatin in 2020 and is now held by Cosette Pharmaceuticals.

How it is thought to work

According to the FDA label, bremelanotide switches on several melanocortin receptor types, most strongly MC1R, then MC4R, MC3R, MC5R and MC2R. At the levels reached in treatment, the label says binding to MC1R and MC4R matters most. Nerve cells carrying MC4R are found in many parts of the brain and spinal cord. The label states plainly that how Vyleesi improves HSDD in women is unknown.

More on how it works

MC1R sits on melanocytes, the skin cells that make pigment. The label says switching on this receptor increases pigment, which fits with the dark patches some users developed.

In female rat studies reviewed in 2007, bremelanotide increased behaviors that researchers took as signs of sexual interest, and appeared to act in a brain area called the medial preoptic area. In a 2022 brain-scan study of 31 women with HSDD, the drug changed activity in several brain regions while women viewed erotic images, compared with placebo. These findings suggest a brain-based action, but they do not prove why some women in trials reported more desire.

What is established in people

Two identical 24-week placebo-controlled trials in 1,267 premenopausal women with HSDD found that bremelanotide improved desire and distress scores more than placebo, which led to FDA approval in 2019. The extra benefit over placebo was small (about a third of a point on a 1.2 to 6 desire scale), the number of satisfying sexual events did not improve, and far more women on the drug stopped early, often because of nausea. A one-year extension had no placebo group. There is no approval for men, the published trials in men are small, early or under an expression of concern, and none of the human studies tested the "PT-141" products sold online.

What the studies found

10 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2022

    Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

    Compared with placebo, the drug increased reported sexual desire for up to 24 hours.

    Full finding, who was studied, and limits

    Who: 31 premenopausal heterosexual women with HSDD, in a randomized, double-blind, placebo-controlled crossover study with brain scans (functional MRI), at Imperial College London. ClinicalTrials.gov lists bremelanotide as the study drug.

    Compared with placebo, the drug increased reported sexual desire for up to 24 hours. While women viewed erotic images, it raised activity in the cerebellum and supplementary motor area, lowered activity in part of the sensory cortex, and increased connections between the amygdala and insula. The authors suggested it may reduce self-consciousness and sensitize women to erotic cues.

    Read with care: Small and short. Brain-scan changes are hard to interpret and do not show lasting benefit. Partly funded by AMAG Pharmaceuticals, which then held the US rights.

    Journal of Clinical Investigation (NCT04179734) · pubmed.ncbi.nlm.nih.gov

  2. Human trial2020

    Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide (AMAG-BMT-HSDD-102)

    Pre-treatment with oral ondansetron did not reduce the rate of nausea compared with placebo.

    Full finding, who was studied, and limits

    Who: 228 healthy women randomized to the anti-nausea drug ondansetron or placebo before a single dose of bremelanotide.

    Pre-treatment with oral ondansetron did not reduce the rate of nausea compared with placebo. The label states it is not recommended for that purpose.

    Read with care: A single-dose study in healthy volunteers. Published in the label, not found as a journal article for this page.

    ClinicalTrials.gov NCT03973047; results in the Vyleesi label, section 6.1 (added by FDA supplement approval, October 2020) · dailymed.nlm.nih.gov

  3. Human trial2019

    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Desire was measured on the Female Sexual Function Index desire score (range 1.2 to 6) and distress on one question about being bothered by low desire (range 0 to 4).

    Full finding, who was studied, and limits

    Who: 1,267 premenopausal women with HSDD, mostly in the United States, average age 39, randomly assigned to bremelanotide or placebo in two identical double-blind trials lasting 24 weeks. 1,247 were in the safety analysis and 1,202 in the efficacy analysis.

    Desire was measured on the Female Sexual Function Index desire score (range 1.2 to 6) and distress on one question about being bothered by low desire (range 0 to 4). Compared with placebo, desire scores rose by an extra 0.30 points in study 301 and 0.42 in study 302 (0.35 combined), and distress scores fell by an extra 0.37 and 0.29 points (0.33 combined). All were statistically significant. In the FDA label's tables, the average desire score rose by 0.5 and 0.6 points on bremelanotide against 0.2 on placebo, and distress fell by 0.7 against 0.4. The number of satisfying sexual events, a key secondary measure, did not differ from placebo. The authors reported effect sizes against placebo of 0.29 to 0.43 for desire and 0.26 to 0.32 for distress, which by the scale they cite is small to medium. On a question about perceived benefit, 58% on bremelanotide and 35% to 36% on placebo were counted as responders. Nausea, flushing and headache each affected 10% or more.

    Read with care: The effect over placebo was modest, and placebo responses were high. Far more women on bremelanotide stopped early (40% against 13% in one study, 39% against 25% in the other, per the FDA label), which complicates the results. Outcomes were self-reported questionnaires. The trials were sponsored by Palatin and AMAG, the companies developing the drug, and several authors worked for them. Only premenopausal women were studied, 86% of them white.

    Obstetrics and Gynecology (RECONNECT studies 301 and 302; NCT02333071, NCT02338960) · pubmed.ncbi.nlm.nih.gov

  4. Human trial2019

    Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    No new safety signals were reported.

    Full finding, who was studied, and limits

    Who: Women who finished the 24-week RECONNECT trials without a serious adverse event could join a 52-week extension in which everyone received bremelanotide. Of 856 eligible women, 684 joined and 272 completed it.

    No new safety signals were reported. The most common drug-related side effects were nausea (40.4%), flushing (20.6%) and headache (12.0%). From the start of the core trials to the end of the extension, desire scores rose by 1.25 to 1.30 points and distress scores fell by 1.4 to 1.7 points in women who had been on bremelanotide throughout. In women who had been on placebo in the core trials, the changes were 0.70 to 0.77 and -0.9.

    Read with care: No placebo group and all analyses were descriptive, so the improvements cannot be credited to the drug. Fewer than half of those who started the extension completed it (272 of 684), and women who did well were more likely to stay, which flatters the averages. Sponsored by the developers.

    Obstetrics and Gynecology (RECONNECT open-label extension) · pubmed.ncbi.nlm.nih.gov

  5. Human trial2019

    Ambulatory blood pressure monitoring study AMAG-BMT-HSDD-101 (as reported in the Vyleesi label and FDA review)

    After 8 days, average daytime blood pressure was 1.9 mmHg higher (systolic) and 1.7 mmHg higher (diastolic) than at the start.

    Full finding, who was studied, and limits

    Who: 127 healthy premenopausal women whose blood pressure was recorded around the clock in an 8-day open-label study, followed by a randomized withdrawal period. The FDA had asked for this study after earlier trials could not show how long blood pressure effects lasted.

    After 8 days, average daytime blood pressure was 1.9 mmHg higher (systolic) and 1.7 mmHg higher (diastolic) than at the start. The peak average rise was 2.8 mmHg systolic and 2.7 mmHg diastolic within the first hours after a dose, with a small fall in heart rate. Readings 12 to 24 hours later were similar to before. Separately, the label reports peak rises of up to 6 mmHg systolic and 3 mmHg diastolic in clinical studies, usually gone within 12 hours.

    Read with care: Healthy volunteers over a short period, so it does not show long-term heart risk. An FDA reviewer raised concern that people already on blood pressure medicines might have longer-lasting rises, based on a separate drug interaction study. The label contraindicates use in people with uncontrolled high blood pressure or known heart disease.

    FDA Vyleesi prescribing information, section 12.2; FDA multidiscipline review, NDA 210557 · dailymed.nlm.nih.gov

  6. Human trial2016

    Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial

    For the two higher dose groups combined against placebo, satisfying sexual events per month rose by 0.7 against 0.2, the total sexual function score by 3.6 against 1.9, and the total distress score fell by 11.1 against 6.8.

    Full finding, who was studied, and limits

    Who: Premenopausal women with female sexual arousal disorder, HSDD, or both. 397 were randomized to placebo or one of three bremelanotide dose levels for 12 weeks; 327 were in the efficacy analysis.

    For the two higher dose groups combined against placebo, satisfying sexual events per month rose by 0.7 against 0.2, the total sexual function score by 3.6 against 1.9, and the total distress score fell by 11.1 against 6.8. All differences were statistically significant. Side effects were nausea, flushing and headache. Ambulatory blood pressure monitoring showed small, short-lived rises of about 3 mmHg in the first four hours after dosing. The paper says this monitoring was added to address FDA concerns raised after earlier studies of a nasal-spray form.

    Read with care: Mid-sized, 12 weeks, and the main result comes from pooling two dose groups. It found an improvement in satisfying sexual events that the later, larger phase 3 trials did not confirm. Funded by Palatin, and several authors were Palatin employees.

    Women's Health (London) (NCT01382719, phase 2b) · pubmed.ncbi.nlm.nih.gov

  7. Human trial2008

    Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study

    The authors reported a positive result in 33.5% on bremelanotide against 8.5% on placebo, greater intercourse satisfaction, and more drug-related side effects with bremelanotide.

    Full finding, who was studied, and limits

    Who: 342 married men aged 28 to 59 with erectile dysfunction who had not responded to sildenafil (Viagra), randomly assigned to a bremelanotide nasal spray (172) or placebo (170), in Iran.

    The authors reported a positive result in 33.5% on bremelanotide against 8.5% on placebo, greater intercourse satisfaction, and more drug-related side effects with bremelanotide.

    Read with care: Treat with strong caution. In 2023 the Journal of Urology published an expression of concern about this paper. A 2008 bremelanotide trial in women by the same author was retracted by the Journal of Sexual Medicine after the author did not provide original data. This is the largest published trial in men found for this page.

    Journal of Urology · pubmed.ncbi.nlm.nih.gov

  8. Human trial2006

    An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

    More women reported moderate or high sexual desire after bremelanotide than after placebo (P = 0.0114).

    Full finding, who was studied, and limits

    Who: 18 premenopausal women with female sexual arousal disorder. Each received a single nasal-spray dose of bremelanotide and of placebo in random order (crossover design), in a clinic.

    More women reported moderate or high sexual desire after bremelanotide than after placebo (P = 0.0114). Blood flow in the vagina, measured while watching erotic videos, did not change significantly compared with placebo.

    Read with care: Very small, single-dose pilot study using a nasal spray that was later dropped. Written by Palatin staff and collaborators.

    Journal of Sexual Medicine · pubmed.ncbi.nlm.nih.gov

  9. Human trial2004

    Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

    Above a certain dose level, PT-141 produced erections that were statistically significant compared with placebo, measured with a device worn on the penis, with the first erection at about 30 minutes.

    Full finding, who was studied, and limits

    Who: Healthy men and men with mild to moderate erectile dysfunction who responded to Viagra, in early-stage (phase 1-type) studies of a nasal spray. The abstract does not give the number of participants.

    Above a certain dose level, PT-141 produced erections that were statistically significant compared with placebo, measured with a device worn on the penis, with the first erection at about 30 minutes. Flushing and nausea were the most common side effects. The authors reported no clinically significant changes in vital signs.

    Read with care: Small, short laboratory studies run by the developer's own scientists. This program in men did not lead to an approved product, and the FDA review records that the nasal-spray application for erectile dysfunction was withdrawn in 2017.

    International Journal of Impotence Research · pubmed.ncbi.nlm.nih.gov

  10. Review2007

    Bremelanotide: an overview of preclinical CNS effects on female sexual function

    Bremelanotide increased solicitation behaviors (which researchers treat as signs of sexual interest) without changing other sexual behaviors, whether given under the skin or directly into certain brain regions, including the medial preoptic area.

    Full finding, who was studied, and limits

    Who: Review of studies in female rats whose ovaries had been removed and who were given hormones.

    Bremelanotide increased solicitation behaviors (which researchers treat as signs of sexual interest) without changing other sexual behaviors, whether given under the skin or directly into certain brain regions, including the medial preoptic area. The authors suggested it may act by activating dopamine signaling there.

    Read with care: Animal behavior is an indirect stand-in for human desire. A review written by researchers in this field rather than a new controlled experiment.

    Journal of Sexual Medicine · pubmed.ncbi.nlm.nih.gov

Safety findings

  • Nausea was the most common side effect in the phase 3 trials: 40% on bremelanotide against 1.3% on placebo. It was most common after the first dose (21%) and dropped to about 3% after later doses. 13% needed anti-nausea medicine and 8% left the trials because of nausea. Source: dailymed.nlm.nih.gov
  • Other common side effects in the label table (bremelanotide against placebo): flushing 20.3% against 0.3%; injection site reactions 13.2% against 8.4%; headache 11.3% against 1.9%; vomiting 4.8% against 0.2%; cough 3.3% against 1.3%; fatigue 3.2% against 0.5%. 18% stopped treatment because of side effects, against 2% on placebo. Serious adverse reactions were reported in 1.1% against 0.5%. Source: dailymed.nlm.nih.gov
  • Blood pressure and heart rate: blood pressure rises briefly and heart rate falls slightly after each dose, with peak rises of up to 6 mmHg systolic and 3 mmHg diastolic 2 to 4 hours after a dose, usually back to baseline within 12 hours. The label contraindicates (forbids) use in people with uncontrolled high blood pressure or known cardiovascular disease, and says it is not recommended for people at high risk of cardiovascular disease. Source: dailymed.nlm.nih.gov
  • Focal hyperpigmentation (darkening of patches of skin, including the face, gums and breasts) occurred in 1% of women in the phase 3 trials and none on placebo. In another study in which it was given much more often, 38% developed dark patches. Women with darker skin were more likely to be affected, and the label says the patches did not clearly fade in all women after stopping. Source: dailymed.nlm.nih.gov
4 more safety findings
  • Drug interactions in the label: bremelanotide may slow stomach emptying and so delay or reduce absorption of medicines taken by mouth; it lowered blood levels of oral naltrexone (a treatment for alcohol and opioid addiction) and of the painkiller indomethacin. The label says to avoid combining it with oral naltrexone products used for addiction. Source: dailymed.nlm.nih.gov
  • Pregnancy and breastfeeding: animal studies in dogs and mice suggested possible harm to the fetus, and the label advises effective contraception and stopping if pregnancy is suspected. Human pregnancy data are too few to judge (7 pregnancies in trials). A study in 10 breastfeeding women (NCT06867835, started July 2025) found the drug passes into breast milk in amounts the label calls clinically insignificant; effects on infants were not studied. FDA approved this label update on October 22, 2026. Source: accessdata.fda.gov
  • Liver: one case of acute hepatitis (liver inflammation) occurred in the open-label extension; liver tests returned to normal four months after stopping, and the label says a role of the drug could not be ruled out. There was no wider liver signal in the development program. Source: dailymed.nlm.nih.gov
  • Unapproved "PT-141" products: there are no human safety studies of products sold online as "research use only". The FDA's August 2026 warning letters classed such products as unapproved new drugs. Source: fda.gov

Rules and status

FDA-approved prescription medicine (Vyleesi, NDA 210557, approved June 21, 2019), now held and marketed by Cosette Pharmaceuticals. Approved only for premenopausal women with acquired, generalized HSDD. Not approved for postmenopausal women, for men, or to enhance sexual performance. "PT-141" sold online as a research chemical is an unapproved new drug in the FDA's view.

The full history, with dates

Approval: the FDA approved Vyleesi on June 21, 2019 as a new molecular entity, with the approval letter addressed to AMAG Pharmaceuticals. A supplement approved on October 23, 2020 added the ondansetron nausea study to the label and recorded a change of applicant name due to transfer of ownership, with the letter addressed to Palatin Technologies. A supplement approved on October 22, 2026, addressed to Cosette Pharmaceuticals, updated section 8 (use in specific populations) and the patient leaflet based on the final report of a required breastfeeding study. The current DailyMed label (version published November 9, 2026) names Cosette Pharmaceuticals as the marketer, and Drugs@FDA lists Cosette as the applicant. The indication and limitations of use are unchanged since approval. Compounding: bremelanotide does not appear in FDA's list of bulk substances nominated for 503A compounding (categories 1 to 3, updated May 14, 2026), and is not in HHS Appendix A of the draft 503A peptide enforcement-discretion policy (Federal Register notice of October 30, 2026, 91 FR 68526), which names six other peptides. FDA's 503A page (current as of May 14, 2026) says state-licensed pharmacies may compound from bulk substances that are components of FDA-approved drugs when no USP or NF monograph exists; bremelanotide is the active ingredient of an approved drug, but whether, and how far, compounded bremelanotide is lawful was not settled from an FDA source for this page. Any compounded version is not FDA-approved. Research-use products: on August 24, 2026 the FDA's Center for Drug Evaluation and Research sent warning letters to online sellers, including TXP Innovations LLC (Tex Peptides), that named "PT-141 (Bremelanotide)" and stated that "these products are unapproved new drugs", adding that despite "research use only" and "not for human or veterinary use" labels, evidence from the website showed the products were intended as drugs for human use. Melanotan II, a different molecule, appears on FDA's page of bulk substances that may present significant safety risks (current as of April 22, 2026), in the table of substances nominated but withdrawn, where FDA notes published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. That entry is about melanotan II, not bremelanotide.

Source: dailymed.nlm.nih.gov (source dated 2026-11-09)

In sport: Not named on the WADA 2026 Prohibited List or the 2027 List (in force January 1, 2027); a full-text search of both lists and the 2027 explanatory note found no mention of bremelanotide or PT-141. Class S0 (non-approved substances) covers any substance not addressed elsewhere on the List "and with no current approval by any governmental regulatory health authority for human therapeutic use". Bremelanotide has a current FDA approval, so on the face of that wording S0 would not apply, but WADA has not published a ruling on it that was found. Class S2 also prohibits listed peptide hormones "and other substances with similar chemical structure or similar biological effect(s)"; whether any WADA body would apply that clause to bremelanotide is unknown. Athletes should check with their anti-doping organization rather than rely on this page. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
"PT-141" sold online is the same thing as Vyleesi.Vyleesi is a sterile, FDA-approved prescription product made under FDA oversight. In August 2026 the FDA told online sellers that their "PT-141 (Bremelanotide)" products were unapproved new drugs, and that "research use only" labels did not change that. None of the trials on this page tested those products. Source: fda.gov
It is a strong libido booster.In the two phase 3 trials, desire scores rose by only an extra 0.30 to 0.42 points over placebo on a scale from 1.2 to 6, distress scores fell by an extra 0.29 to 0.37 points on a 0 to 4 scale, and the number of satisfying sexual events did not differ from placebo. Source: pubmed.ncbi.nlm.nih.gov
It works for men and for erectile dysfunction.The FDA label states it is not indicated for HSDD in men. Published studies in men are small and early, or, in the largest one (342 men), carry a 2023 expression of concern. The nasal-spray program for erectile dysfunction was withdrawn and never approved. No bremelanotide trial limited to men was found on ClinicalTrials.gov. Source: dailymed.nlm.nih.gov
It enhances sexual performance.The label states plainly that Vyleesi "is not indicated to enhance sexual performance". It was studied only in premenopausal women with a diagnosed desire disorder. Source: dailymed.nlm.nih.gov
It is basically melanotan II, so it is a tanning peptide too, or melanotan II is just as safe.They are different molecules that differ at one end of the chain (PubChem). Melanotan II has no FDA approval, and FDA lists published case reports of serious harms with it, including melanoma and priapism. Bremelanotide itself can cause patches of dark skin, which the label treats as a side effect, not a benefit. Source: fda.gov
It has no real side effects.In the phase 3 trials, 40% had nausea, 20% flushing and 11% headache, and 18% stopped treatment because of side effects against 2% on placebo. It briefly raises blood pressure after each dose and must not be used by people with uncontrolled high blood pressure or known heart disease. Source: dailymed.nlm.nih.gov

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match bremelanotide's free-base molecular weight of about 1025.2 (PubChem monoisotopic mass 1024.524 Da). Melanotan II differs by less than one mass unit (PubChem monoisotopic mass 1023.540 Da, carboxamide instead of acid), so a low-resolution test may not tell them apart. A report should show enough resolution, or a fragmentation pattern, to separate the two.
  • Purity by HPLC (a method that separates a sample into its parts), with the actual chromatogram, the purity percentage, and any impurity peaks listed. Ring-closure failures, missing or swapped amino acids, and the wrong mirror-image form of phenylalanine (L instead of D) are realistic impurities for a cyclic peptide like this.
  • Salt form and content: the medicine uses the acetate salt. A report should say whether it measured peptide content (net peptide) or total powder weight, since salt and water can make up part of the powder.
  • Traceability: the report should name the testing laboratory, the lot or batch number and the test date, and the lot should match the product.
  • What a lab report cannot do: a certificate of analysis does not make a product FDA-approved, and it does not show sterility or freedom from bacterial toxins unless those tests were run and reported. The FDA has stated that "PT-141" products sold this way are unapproved new drugs.

How to read a lab report

What is not known

  • Whether bremelanotide is a metabolite of melanotan II. The two structures differ only at the C-terminus (PubChem), and the claim is widely repeated, but no journal article or regulatory document confirming it was found.
  • Why and exactly when the nasal-spray program was stopped. A 2016 trial paper says blood pressure monitoring was added because of FDA concerns after earlier nasal-spray studies, and the FDA review says the move to injection followed variable absorption from the nose. Secondary sources give 2007 or 2008 and cite blood pressure rises; no primary document stating that was found.
  • The legal status of compounded bremelanotide under section 503A (component of an approved drug, and the limits on copying commercially available drugs) was not confirmed from an FDA source.
  • Whether WADA would treat bremelanotide as prohibited under S2's 'similar biological effect' wording. It is not named, and no WADA statement on it was found.
  • How long the benefit lasts and whether it holds up beyond one year: the 52-week extension had no placebo group and most participants did not complete it.
  • Long-term cardiovascular safety in women with heart risk factors, who were excluded or under-represented in the trials.
  • Whether the dark skin patches always fade after stopping; the label says resolution was not confirmed in all patients.
  • A large phase 2 trial in men with erectile dysfunction is mentioned in secondary sources but was not found and opened for this page. Palatin is also testing bremelanotide with tirzepatide for obesity (NCT06565611, active, not recruiting); no results were looked up.

Sources

All 27 sources
  1. DailyMed: Vyleesi prescribing information and patient leaflet (Cosette; SPL version published November 9, 2026). dailymed.nlm.nih.gov
  2. Drugs@FDA: NDA 210557 overview (approval June 21, 2019; supplements 2020 and 2026). accessdata.fda.gov
  3. FDA approval letter, NDA 210557 (June 21, 2019, to AMAG Pharmaceuticals). accessdata.fda.gov
  4. FDA supplement approval letter S-002 (October 23, 2020, to Palatin Technologies; transfer of ownership). accessdata.fda.gov
  5. FDA supplement approval letter S-005 (October 22, 2026, to Cosette Pharmaceuticals; breastfeeding study). accessdata.fda.gov
  6. FDA multidiscipline review, NDA 210557 (2019). accessdata.fda.gov
  7. PubChem: Bremelanotide (CID 9941379). pubchem.ncbi.nlm.nih.gov
  8. PubChem: Melanotan II (CID 92432). pubchem.ncbi.nlm.nih.gov
  9. Kingsberg et al. 2019, Obstetrics and Gynecology (RECONNECT phase 3). pubmed.ncbi.nlm.nih.gov
  10. Simon et al. 2019, Obstetrics and Gynecology (RECONNECT 52-week extension). pubmed.ncbi.nlm.nih.gov
  11. Clayton et al. 2016, Women's Health (phase 2b dose-finding). pubmed.ncbi.nlm.nih.gov
  12. Diamond et al. 2006, Journal of Sexual Medicine (pilot in women). pubmed.ncbi.nlm.nih.gov
  13. Diamond et al. 2004, International Journal of Impotence Research (nasal spray in men). pubmed.ncbi.nlm.nih.gov
  14. Safarinejad and Hosseini 2008, Journal of Urology (men; expression of concern 2023). pubmed.ncbi.nlm.nih.gov
  15. Safarinejad 2008, Journal of Sexual Medicine (women; retracted). pubmed.ncbi.nlm.nih.gov
  16. Thurston et al. 2022, Journal of Clinical Investigation (brain imaging). pubmed.ncbi.nlm.nih.gov
  17. Pfaus et al. 2007, Journal of Sexual Medicine (preclinical review). pubmed.ncbi.nlm.nih.gov
  18. ClinicalTrials.gov: studies with bremelanotide as intervention. clinicaltrials.gov
  19. FDA warning letter: TXP Innovations LLC dba Tex Peptides (August 24, 2026). fda.gov
  20. FDA: bulk drug substances that may present significant safety risks (current as of April 22, 2026). fda.gov
  21. FDA: 503A nominated bulk substances by category (updated May 14, 2026). fda.gov
  22. FDA: bulk drug substances used in compounding under section 503A (current as of May 14, 2026). fda.gov
  23. HHS 503A peptide enforcement-discretion policy, Appendices A and B (draft). hhs.gov
  24. Federal Register notice, October 30, 2026 (91 FR 68526). govinfo.gov
  25. WADA 2026 Prohibited List. wada-ama.org
  26. WADA: publication of the 2027 Prohibited List (September 21, 2026). wada-ama.org
  27. WADA 2027 List explanatory note. wada-ama.org

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.